Login to Your Account

Financings Roundup

Friday, March 18, 2011
Threshold Pharmaceuticals Inc., of Redwood City, Calif., completed its $30 million registered direct offering of 14.3 million shares and warrants for about 5.7 million shares. Net proceeds are expected to be about $27.8 million and will be used to support clinical trials of TH-302 and for additional product discovery R&D, working capital and other general corporate purposes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription